Larimar Therapeutics, Inc. LRMR R2K

Healthcare · Biotechnology · United States

https://www.larimartx.com

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.

Market & Price

Market Cap

$361.51M

Current Price

$3.48

High / Low (52W)

$5.95 / $2.20

Beta

0.91

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

PEG Ratio

Book Value

$1.51

Price to Book

2.30

P/S

EV/EBITDA

-0.97

Dividend Yield

Profitability & Returns

ROCE

ROE

-109.83%

ROA

-56.92%

Profit Margin

0.00%

Op Margin

0.00%

EPS (Latest Qtr)

$-0.31

EPS (TTM)

$-2.12

Balance Sheet & Liquidity

Debt/Equity

2.39

Quick Ratio

4.21

Current Ratio

4.29

Debt

$3.78M

Total Assets

$145.84M

Current Assets

$142.02M

Working Capital

$77.23M

Ownership

Promoter Holding

1.10%

Chg in Prom Hold

FII / Inst Holding

85.55%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$166.65M

Total Revenue (TTM)

EBITDA

$-172.10M

Free Cash Flow

$-71.31M

Operating Cash Flow

$-131.28M

Shares Outstanding

103.88M

Gross Margin

0.00%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

Profit 5Y

-122.87%

Revenue (YoY)

Earnings (YoY)

PROS

In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Earnings shrank at -122.9% CAGR over 5 years.
Trading 41.5% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	LRMR Larimar Therapeutics, Inc. R2K	3.48	-	$361.51M	-	-	-109.83%	-	-122.87%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	31.19M	27.79M	49.50M	64.02M	31.12M
Operating Income	-13.24M	-17.61M	-19.72M	-	-17.86M	-15.06M	-14.83M	-	-13.27M	-13.54M	-12.84M	-	-15.70M	-15.56M	-15.17M	-	-13.28M	-3.70M	-8.63M	-	-6.67M	-11.40M	-10.34M	-12.11M	-12.54M	-16.73M	-8.89M	-8.69M	-8.51M	-7.64M	-9.62M	-10.34M	-16.73M	-24.60M	-18.26M	-31.19M	-27.79M	-49.50M	-64.02M	-31.12M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-31.10M	-27.70M	-49.41M	-63.93M	-31.05M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-29.28M	-26.18M	-47.71M	-62.50M	-29.61M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-13.47M	-17.76M	-19.88M	-	-17.74M	-15.03M	-14.68M	-	-13.01M	-13.35M	-12.59M	-	-15.96M	-15.78M	-15.07M	-14.57M	-4.72M	-3.70M	-8.63M	-7.25M	-6.67M	-11.33M	-10.27M	-12.09M	-12.61M	-16.80M	-8.94M	-8.67M	-8.32M	-6.53M	-8.37M	-9.06M	-14.65M	-21.63M	-15.50M	-29.28M	-26.18M	-47.71M	-62.50M	-29.61M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1.21	-0.64	-0.76	-0.79	-0.92	-0.49	-0.47	-0.37	-0.15	-0.19	-0.21	-0.27	-0.34	-0.24	-0.46	-0.41	-0.61	-0.73	-0.31
R&D Expense	10.21M	12.53M	14.17M	-	12.50M	10.16M	10.00M	-	9.68M	10.53M	9.72M	-	12.43M	12.21M	11.83M	-	9.63M	3.13M	8.03M	-	5.01M	8.91M	6.92M	8.97M	9.10M	14.03M	5.81M	5.64M	5.58M	4.56M	5.88M	6.58M	12.94M	19.68M	13.92M	26.55M	23.37M	44.93M	-	25.03M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	0	0	0	0	0	0	0	0	-	-	0	0	0	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	36.53M	41.76M	90.89M	172.50M
Operating Income	-13.79M	-13.78M	-35.53M	-73.81M	-58.23M	-53.00M	-61.12M	-23.21M	-42.80M	-50.47M	-36.53M	-41.76M	-90.89M	-172.50M
EBITDA	-	-	-	-	-	-	-	-	-	-	-36.21M	-41.45M	-90.57M	-172.15M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-35.35M	-36.95M	-80.60M	-165.67M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-13.88M	-14.03M	-36.48M	-74.29M	-57.88M	-52.03M	-61.37M	-23.13M	-42.48M	-50.64M	-35.35M	-36.95M	-80.60M	-165.67M
Diluted EPS	-	-	-	-	-	-	-	-	-3.57	-2.95	-1.37	-0.84	-1.32	-2.27
R&D Expense	11.54M	9.56M	27.39M	54.62M	39.94M	40.84M	47.93M	20.79M	31.41M	38.40M	24.25M	27.67M	73.28M	154.22M

Compounded Sales Growth

5 Years:	-
1 Year:	-

Compounded Profit Growth

5 Years:	-122.87%
1 Year:	-

Stock Price Performance

1 Year:	+54.67%
6 Months:	-5.18%
3 Months:	-34.46%
1 Month:	-19.82%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	38.14M	117.52M	189.11M	131.62M	105.51M	121.76M	5.20M	104.69M	-	126.41M	95.94M	200.22M	145.84M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	120.74M	90.17M	195.30M	142.02M
Cash & Equivalents	1.47M	9.94M	35.52M	58.10M	35.59M	32.35M	40.78M	49.33M	1.01M	68.15M	-	26.82M	26.75M	33.22M	85.41M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-	-	-	-	-	0	332.00K	1.05M	747.00K
Total Liabilities	-	-	2.92M	13.08M	20.00M	9.89M	27.29M	28.49M	5.89M	14.99M	-	15.50M	14.21M	28.41M	67.76M
Current Liabilities	-	-	2.92M	6.90M	16.54M	9.89M	7.29M	13.31M	5.89M	8.99M	-	10.71M	9.51M	24.36M	64.80M
Long Term Debt	-	-	-	-	-	3.18M	20.00M	20.00M	14.54M	-	-	-	-	-	-
Total Debt	-	-	-	-	-	-	-	-	-	-	-	5.41M	5.55M	5.12M	4.07M
Total Equity	-40.92M	-54.73M	-68.57M	104.44M	169.11M	121.73M	78.22M	2.91M	-694.00K	89.69M	-	110.90M	81.72M	171.81M	78.08M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	43.27M	43.91M	63.82M	83.09M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	-	-	-51.98M	-43.78M	-51.49M	-22.70M	-42.20M	-	-27.57M	-33.46M	-70.76M	-113.20M
Investing Cash Flow	-	-	-	-	51.45M	35.65M	-6.87M	-83.00K	17.09M	-	-90.96M	33.35M	-85.39M	100.31M
Financing Cash Flow	-	-	-	-	-2.71M	16.56M	66.91M	19.39M	93.59M	-	75.26M	30.00K	161.88M	65.09M
Capital Expenditure	-2.00K	-17.00K	-58.00K	-595.00K	-660.00K	-55.00K	-108.00K	-83.00K	-62.00K	-	-100.00K	-164.00K	-515.00K	-91.00K
Free Cash Flow	-	-	-	-	-52.63M	-43.84M	-51.59M	-22.78M	-42.26M	-	-27.67M	-33.62M	-71.28M	-113.29M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-43.27M	-76.00K	5.74M	52.19M

Ratios (Annual)

Figures in %.

Metric	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-
ROE %	25.4%	20.5%	-34.9%	-43.9%	-47.5%	-66.5%	-2,106.0%	3,333.1%	-47.4%	-	-31.9%	-45.2%	-46.9%	-212.2%
ROCE %	-	-39.1%	-32.1%	-42.8%	-47.8%	-54.0%	-56.4%	3,345.0%	-44.7%	-	-31.6%	-48.3%	-51.7%	-212.8%

Shareholding Pattern

Insiders

1.10%

Institutions

85.55%

Public Float

86.50%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Deerfield Management Company, L.P	34.28%	35.61M	$123.91M
2	Blue Owl Capital Holdings LP	6.85%	7.12M	$24.78M
3	Blackrock Inc.	3.61%	3.75M	$13.06M
4	Millennium Management Llc	3.49%	3.63M	$12.62M
5	AIGH Capital Management LLC	2.89%	3.00M	$10.44M
6	Driehaus Capital Management, LLC	2.82%	2.93M	$10.21M
7	Vanguard Capital Management LLC	2.76%	2.87M	$9.97M
8	DAFNA Capital Management, LLC	1.95%	2.03M	$7.06M
9	Goldman Sachs Group Inc	1.50%	1.56M	$5.43M
10	RTW Investments LP	1.44%	1.50M	$5.22M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for LRMR

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Sector	Healthcare
Industry	Biotechnology
Headquarters	United States
Employees	71
Website	https://www.larimartx.com

Larimar Therapeutics, Inc. LRMR R2K

Market & Price

Valuation

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Growth (CAGR)

PROS

CONS

Price Chart

Technical Trend

Fundamental Growth

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Explore More